{"id":559684,"date":"2026-06-13T05:00:00","date_gmt":"2026-06-13T03:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/dermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii\/"},"modified":"2026-06-18T17:17:48","modified_gmt":"2026-06-18T15:17:48","slug":"dermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/dermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii\/","title":{"rendered":"Dermatitis at\u00f3pica: novedades interesantes sobre los candidatos a f\u00e1rmacos en fase III"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Con motivo del congreso anual de 2026 de <em>la Academia Americana de Dermatolog\u00eda<\/em> (AAD), se presentaron, entre otros, datos de estudios de \u00faltima hora sobre el amlitelimab y el rademikibart en las sesiones de \u00abLate-Breaking Research\u00bb. Los resultados obtenidos ponen de relieve el potencial terap\u00e9utico de estos candidatos a f\u00e1rmacos: se alcanzaron los criterios de valoraci\u00f3n clave, el perfil de seguridad result\u00f3 favorable en general y, al igual que otros representantes de los anticuerpos monoclonales, tanto el amlitelimab como el rademikibart destacan por su c\u00f3modo uso a largo plazo.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fdermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Con motivo del congreso anual de 2026 de la Academia Americana de Dermatolog\u00eda (AAD), se presentaron, entre otros, datos de estudios de \u00faltima hora sobre el amlitelimab y el rademikibart&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fdermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":559685,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Lo m\u00e1s destacado de la Reuni\u00f3n Anual de la AAD","footnotes":""},"category":[11552,11298,11310,11483,11475],"tags":[95040,84894,68893,95115,95119,12531,95121,95112,95116,27685],"powerkit_post_featured":[],"class_list":["post-559684","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-alergologia-e-inmunologia-clinica","category-dermatologia-y-venereologia","category-el-congreso-informa","category-estudios","tag-academia-americana-de-dermatologia","tag-amlitelimab-es","tag-candidatos-a-farmacos","tag-coast-1","tag-coast-2","tag-dermatitis-atopica","tag-radiant-ad","tag-reunion-anual-de-la-aad-2","tag-shore","tag-uso-a-largo-plazo","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-28 05:42:59","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/559684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=559684"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/559684\/revisions"}],"predecessor-version":[{"id":559686,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/559684\/revisions\/559686"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/559685"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=559684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=559684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=559684"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=559684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}